MarketStudyReport.com adds “Multiple Sclerosis -Canada Drug Forecast and Market Analysis to 2024” new report to its research database. The report spread across 231 pages with table and figures in it.
Canada was the third-largest MS market in the 10MM in 2014, with DMT sales totaling $1.2 billion. Steady growth is anticipated to occur between 2014 and 2020 as a result of novel pipeline agents with improved clinical profiles entering the market and the continued uptake of products with a high ACOT. The market is then expected to plateau until 2024 as generic erosion of key brands, including Tecfidera, Aubagio, and Gilenya, offsets potential growth driven by pipeline drug uptake.
Browse full table of contents and data tables at https://www.marketstudyreport.com/reports/multiple-sclerosis-canada-drug-forecast-and-market-analysis-to-2024/
Multiple Sclerosis (MS) is an inflammatory autoimmune disease of the central nervous system which leads to neurological disability. The exact underlying cause of the disease is poorly understood; however, it appears to involve a complex combination of genetic susceptibility and a non-genetic trigger. The MS therapeutics market has entered an exciting phase, with an upsurge of available treatment options. Over the forecast period, patients are expected to continue to switch to the oral disease-modifying therapies (DMTs), lessening the stronghold of the established injectable treatments. There are also several promising products in the late-stage pipeline, with a diverse range of mechanisms offering clinical advantages intended to address unmet needs. Both pipeline and marketed DMTs are seeking approval for the treatment of progressive MS, which currently represents a significant unmet need. These factors are expected to increase treatment rates throughout the 10MM resulting, driving market growth. However, this will be largely offset by brand erosion due to the emergence of biosimilars and generic small molecules.
-Overview of MS including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
-Detailed information on the key drugs in Canada including product MScription, safety and efficacy profiles as well as a SWOT analysis.
-Sales forecast for the top drugs in Canada from 2014-2024.
-Analysis of the impact of key events as well the drivers and restraints affecting Canada MS market.
Reasons to buy
-Understand and capitalize by identifying products that are most likely to ensure a robust return
-Stay ahead of the competition by understanding the changing competitive landscape for MS.
-Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
-Make more informed business decisions from insightful and in-depth analysis of drug performance
-Obtain sales forecast for drugs from 2014-2024 in Canada.
To receive personalized assistance write to us @ firstname.lastname@example.org with the report title in the subject line along with your questions or call us at +1 866-764-2150